Cardiomyopathy

April 26, 2019

Autologous blood transfusion functions as a cardioprotective agent: Autologous blood transfusion-based therapy for Cardiomyopathy: Autologous blood transfusion decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy, via upregulation of its target gene, 26/April/2019, 7.00 pm

Autologous blood transfusion functions as a cardioprotective agent: Autologous blood transfusion-based therapy for Cardiomyopathy: Autologous blood transfusion decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy, via upregulation of its target gene, 26/April/2019, 7.00 pm https://genomediscovery.org/wp-content/uploads/2019/04/Autologous-blood-transfusion-promotes-cardiomyocyte-dedifferentiation-and-proliferation-and-attenuates-cardiomyopathy-through-down-regulation-of-Sox6.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Autologous-blood-transfusion-promotes-cardiomyocyte-dedifferentiation-and-proliferation-and-attenuates-cardiomyopathy-through-down-regulation-of-Sox6.jpg2_.jpg April 26, 2019 April 26, 2019

Introduction: What they say A study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart function through microRNA-mediated Sox6 repression.” This study…

April 9, 2019

Intracardiac injection of Lansoprazole promotes heart regeneration and repair: Intracardiac injection of Lansoprazole (trade name: Prevacid) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 9/April/2019, 11.00 pm

Intracardiac injection of Lansoprazole promotes heart regeneration and repair: Intracardiac injection of Lansoprazole (trade name: Prevacid) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 9/April/2019, 11.00 pm https://genomediscovery.org/wp-content/uploads/2019/04/Lanzoprazole-increases-cardiomyocyte-proliferation.regeneration-enhances-cardiac-contractility-and-attenuates-pathogenesis-associated-with-myocardial-infarction.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Lanzoprazole-increases-cardiomyocyte-proliferation.regeneration-enhances-cardiac-contractility-and-attenuates-pathogenesis-associated-with-myocardial-infarction.jpg April 9, 2019 April 9, 2019

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and…

April 8, 2019

Molecular therapy for cardiac dysfunction: Lansoprazole (trade name: Prevacid), a medication used to decrease stomach acid secretion, decreases Mir-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function, via upregulation of its target gene, 8/April/2018, 11.14 pm

Molecular therapy for cardiac dysfunction: Lansoprazole (trade name: Prevacid), a medication used to decrease stomach acid secretion, decreases Mir-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function, via upregulation of its target gene, 8/April/2018, 11.14 pm https://genomediscovery.org/wp-content/uploads/2019/04/Lanzoprazole-attenuates-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis-through-down-regulation-of-MiR29-and-up-regulation-of-GSK3B-ICAT.CTNNBIP1-and-GLIS2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Lanzoprazole-attenuates-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis-through-down-regulation-of-MiR29-and-up-regulation-of-GSK3B-ICAT.CTNNBIP1-and-GLIS2.jpg April 8, 2019 April 8, 2019

Introduction: What they say: A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich…

March 28, 2019

Intracardiac/Epicardial injection of Erythropoietin protects against Cardiomyopathy: Erythropoietin/Hematopoietin decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy, via upregulation of its target gene, 28/March/2019, 6.38 am

Intracardiac/Epicardial injection of Erythropoietin protects against Cardiomyopathy: Erythropoietin/Hematopoietin decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy, via upregulation of its target gene, 28/March/2019, 6.38 am https://genomediscovery.org/wp-content/uploads/2019/03/Intracardiac.Epicardial-injection-of-Erythropoietin.Hematopoietin-promotes-cardiomyocyte-dedifferentiation-and-proliferation-and-attenuates-cardiomyopathy-through-down-regulation-of-Sox6.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/Intracardiac.Epicardial-injection-of-Erythropoietin.Hematopoietin-promotes-cardiomyocyte-dedifferentiation-and-proliferation-and-attenuates-cardiomyopathy-through-down-regulation-of-Sox6.jpg2_.jpg March 28, 2019 March 28, 2019

Introduction: What they say A recent study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart function through microRNA-mediated Sox6 repression.” This…

March 26, 2019

A sweet way to stay free of cardiac diseases: Sugar-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Trehalose, an artificial sweetener composed of two glucose molecules, increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes, via up-regulation of its target gene, 26/March/2018, 10.29 pm

A sweet way to stay free of cardiac diseases: Sugar-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Trehalose, an artificial sweetener composed of two glucose molecules, increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes, via up-regulation of its target gene, 26/March/2018, 10.29 pm https://genomediscovery.org/wp-content/uploads/2019/03/Trehalose-promotes-Cardiomyocyte-CM-dedifferentiation-and-proliferation-followed-by-redifferentiation-and-regeneration-through-activation-of-Her2.ERBB2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/Trehalose-promotes-Cardiomyocyte-CM-dedifferentiation-and-proliferation-followed-by-redifferentiation-and-regeneration-through-activation-of-Her2.ERBB2_.jpg March 26, 2019 March 26, 2019

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April…

March 25, 2019

Molecular Hydrogen gas-based therapy for heart regeneration and repair: Intracardiac or subcutaneous injection of Hydrogen gas decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 25/March/2019, 2.18 pm

Molecular Hydrogen gas-based therapy for heart regeneration and repair: Intracardiac or subcutaneous injection of Hydrogen gas decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 25/March/2019, 2.18 pm https://genomediscovery.org/wp-content/uploads/2019/03/Intracardiac-or-subcutaneous-injection-or-inhalation-of-hydrogen-gas-increases-cardiomyocyte-proliferation.regeneration-enhances-cardiac-contractility.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/Intracardiac-or-subcutaneous-injection-or-inhalation-of-hydrogen-gas-increases-cardiomyocyte-proliferation.regeneration-enhances-cardiac-contractility.jpg2_.jpg March 25, 2019 March 25, 2019

Popular Post